#Bedaquiline access update: This week, Indian patent office rejected Johnson&Johnson's patent application for long-acting injectable bedaquiline, primarily developed for #TB preventive therapy, opening the door for generics —hopefully soon for prevention too. Thanks to #TBactivism #IDSky #TBSky 🥳🥳🥳